Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SYNKIT

Financiado

Cerrado

Synthetic Natural Killer Cells for Immunotherapy

"Cancer remains a leading cause of death worldwide, urging for innovative therapies. Infusion of natural killer (NK) cells, which possess an intrinsic capacity to eliminate cancer cells, is a promising treatment option for various... ver más

31/08/2022

192K€

Presupuesto del proyecto: 192K€

Líder del proyecto

KAROLINSKA INSTITUTET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-08-31

MSCA-IF-2018: Individual Fellowships

I+D

Cerrada hace 6 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

191.85K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

HyperTargIPS-NK Hyper-targeting CAR NK cells from induced pluripotent stem c... 4M€ Cerrado

NATURIMMUN Natural Killer Cell Based Anti Cancer Immunotherapies Resear... 4M€ Cerrado

CNS2023-144487 Inmunidad, infección e inmunoterapia 200K€ Cerrado

CPP2021-008350 Células CAR-NK "off-the-shelf" de próxima generación derivad... 98K€ Cerrado

CINK Advancing cancer immunotherapy using natural killer cells fo... 158K€ Cerrado

CHEMCELL Chemical Engineering of Natural Killer Cells for Cancer Immu... 150K€ Cerrado

Duración del proyecto: 41 meses Fecha Inicio: 2019-03-19
Fecha Fin: 2022-08-31

Líder del proyecto

KAROLINSKA INSTITUTET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 192K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto "Cancer remains a leading cause of death worldwide, urging for innovative therapies. Infusion of natural killer (NK) cells, which possess an intrinsic capacity to eliminate cancer cells, is a promising treatment option for various tumours. Genetic engineering of NK cells before transfer allows to specifically tailor and modulate their anti-tumour responses. One particularly attractive strategy for broad implementation of NK cell immunotherapy in an off-the-shelf setting is to expand large numbers of NK cells from induced pluripotent stem cells (iPSCs). However, this approach is limited by two main bottlenecks: i) poor persistence of allogeneic iPSC-derived NK (iNK) cells due to rejection by the recipient immune system and ii) impaired functionality due to failure to achieve complete differentiation in vitro. The SYNKIT project seeks to address both of these current limitations through genetic engineering of iNK cells for increased persistence and function. Deletion of human leukocyte antigen (HLA) ""self-ligands"" allows the transferred cells to escape from host T cells. However, absence of HLA also triggers missing-self recognition and rejection by host NK cells. In addition, new insights from the host laboratory into the molecular mechanism underlying NK cell education have unravelled a pathway of functional disarming in NK cells that lack self-ligands, further diminishing the anti-tumour efficacy of HLA-deficient NK cells. In SYNKIT, I will use HLA-deficient iNK cells as a platform to assess how introduction of synthetic self-ligands modulates the allogenicity and functionality of iNK cells. The overall goal of SYNKIT is to identify synthetic self-ligands, which reduce recognition by the host immune system and yet prevent functional disarming of the engineered iNK cells, thereby resulting in optimised anti-tumour function. Successful completion of SYNKIT will pave the way for development of next generation immunotherapy to more effectively combat cancer. "

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores